Pharlinde may be available in the countries listed below.
Ingredient matches for Pharlinde
Gliclazide
Gliclazide is reported as an ingredient of Pharlinde in the following countries:
- Japan
International Drug Name Search
Thursday, October 27, 2016
Klaridex
Klaridex may be available in the countries listed below.
Ingredient matches for Klaridex
Clarithromycin
Clarithromycin is reported as an ingredient of Klaridex in the following countries:
- Israel
International Drug Name Search
Wednesday, October 26, 2016
Folinato Calcico Ferrer Farma
Folinato Calcico Ferrer Farma may be available in the countries listed below.
Ingredient matches for Folinato Calcico Ferrer Farma
Calcium Folinate
Calcium Folinate is reported as an ingredient of Folinato Calcico Ferrer Farma in the following countries:
- Spain
International Drug Name Search
FG Troches Meiji
FG Troches Meiji may be available in the countries listed below.
Ingredient matches for FG Troches Meiji
Framycetin
Framycetin sulfate (a derivative of Framycetin) is reported as an ingredient of FG Troches Meiji in the following countries:
- Indonesia
Gramicidin
Gramicidin is reported as an ingredient of FG Troches Meiji in the following countries:
- Indonesia
International Drug Name Search
Tuesday, October 25, 2016
Larither
Larither may be available in the countries listed below.
Ingredient matches for Larither
Artemether
Artemether is reported as an ingredient of Larither in the following countries:
- India
- Myanmar
International Drug Name Search
Fenoxazoline
Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
R01AA12
CAS registry number (Chemical Abstracts Service)
0004846-91-7
Chemical Formula
C13-H18-N2-O
Molecular Weight
218
Therapeutic Category
Vasoconstrictor ORL, local
Chemical Name
1H-Imidazole, 4,5-dihydro-2-[[2-(1-methylethyl)phenoxy]methyl]-
Foreign Names
- Fenoxazolinum (Latin)
- Fenoxazolin (German)
- Fénoxazoline (French)
- Fenoxazolina (Spanish)
Generic Names
- Fénoxazoline (OS: DCF)
- Phenoxazolin (IS)
Brand Name
- Nebulicina
Boehringer Ingelheim, Argentina
International Drug Name Search
Glossary
| DCF | Dénomination Commune Française |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Click for further information on drug naming conventions and International Nonproprietary Names.
Monday, October 24, 2016
Comycetin
Comycetin may be available in the countries listed below.
Ingredient matches for Comycetin
Chloramphenicol
Chloramphenicol is reported as an ingredient of Comycetin in the following countries:
- Ethiopia
International Drug Name Search
Xylonest
Xylonest may be available in the countries listed below.
Ingredient matches for Xylonest
Prilocaine
Prilocaine hydrochloride (a derivative of Prilocaine) is reported as an ingredient of Xylonest in the following countries:
- Germany
- Switzerland
International Drug Name Search
Ran-Perindopril
Ran-Perindopril may be available in the countries listed below.
Ingredient matches for Ran-Perindopril
Perindopril
Perindopril erbumine (a derivative of Perindopril) is reported as an ingredient of Ran-Perindopril in the following countries:
- South Africa
International Drug Name Search
AlternaGEL
In the US, AlternaGEL (aluminum hydroxide systemic) is a member of the drug class antacids and is used to treat Duodenal Ulcer, Erosive Esophagitis, Gastrointestinal Hemorrhage, GERD, Hyperphosphatemia, Indigestion, Peptic Ulcer, Stomach Ulcer and Zollinger-Ellison Syndrome.
US matches:
- Alternagel
Ingredient matches for AlternaGEL
Aluminium Hydroxide
Aluminium Hydroxide hydrate (Algeldrate) (a derivative of Aluminium Hydroxide) is reported as an ingredient of AlternaGEL in the following countries:
- United States
International Drug Name Search
Ranitax
Ranitax may be available in the countries listed below.
Ingredient matches for Ranitax
Ranitidine
Ranitidine is reported as an ingredient of Ranitax in the following countries:
- Chile
- Peru
International Drug Name Search
Ethigent
Ethigent may be available in the countries listed below.
Ingredient matches for Ethigent
Gentamicin
Gentamicin sulfate (a derivative of Gentamicin) is reported as an ingredient of Ethigent in the following countries:
- Indonesia
International Drug Name Search
Sunday, October 23, 2016
Ampisina
Ampisina may be available in the countries listed below.
Ingredient matches for Ampisina
Ampicillin
Ampicillin is reported as an ingredient of Ampisina in the following countries:
- Turkey
International Drug Name Search
Bupibil
Bupibil may be available in the countries listed below.
Ingredient matches for Bupibil
Bupivacaine
Bupivacaine hydrochloride (a derivative of Bupivacaine) is reported as an ingredient of Bupibil in the following countries:
- Italy
International Drug Name Search
Trimetoprim
Trimetoprim may be available in the countries listed below.
Ingredient matches for Trimetoprim
Trimethoprim
Trimetoprim (DCIT) is known as Trimethoprim in the US.
International Drug Name Search
Glossary
| DCIT | Denominazione Comune Italiana |
Click for further information on drug naming conventions and International Nonproprietary Names.
Ramigamma
Ramigamma may be available in the countries listed below.
Ingredient matches for Ramigamma
Ramipril
Ramipril is reported as an ingredient of Ramigamma in the following countries:
- Germany
International Drug Name Search
Clopidogrel Hennig
Clopidogrel Hennig may be available in the countries listed below.
Ingredient matches for Clopidogrel Hennig
Clopidogrel
Clopidogrel besilate (a derivative of Clopidogrel) is reported as an ingredient of Clopidogrel Hennig in the following countries:
- Germany
International Drug Name Search
Captopril Alpharma
Captopril Alpharma may be available in the countries listed below.
Ingredient matches for Captopril Alpharma
Captopril
Captopril is reported as an ingredient of Captopril Alpharma in the following countries:
- Portugal
International Drug Name Search
Miokacin
Miokacin may be available in the countries listed below.
Ingredient matches for Miokacin
Midecamycin
Midecamycin is reported as an ingredient of Miokacin in the following countries:
- Italy
International Drug Name Search
Saturday, October 22, 2016
Risperidona Genkern
Risperidona Genkern may be available in the countries listed below.
Ingredient matches for Risperidona Genkern
Linezolid
Linezolid is reported as an ingredient of Risperidona Genkern in the following countries:
- Malta
Risperidone
Risperidone is reported as an ingredient of Risperidona Genkern in the following countries:
- Spain
International Drug Name Search
Ciprofloxacino Combix
Ciprofloxacino Combix may be available in the countries listed below.
Ingredient matches for Ciprofloxacino Combix
Ciprofloxacin
Ciprofloxacin hydrochloride (a derivative of Ciprofloxacin) is reported as an ingredient of Ciprofloxacino Combix in the following countries:
- Spain
International Drug Name Search
Ratinol
Ratinol may be available in the countries listed below.
Ingredient matches for Ratinol
Retinol
Retinol palmitate (a derivative of Retinol) is reported as an ingredient of Ratinol in the following countries:
- Bangladesh
International Drug Name Search
Carboplatin Teva
Carboplatin-Teva may be available in the countries listed below.
Ingredient matches for Carboplatin-Teva
Carboplatin
Carboplatin is reported as an ingredient of Carboplatin-Teva in the following countries:
- Czech Republic
- Hungary
- Latvia
- Poland
- Sweden
- Switzerland
- Turkey
International Drug Name Search
Gammamix
Gammamix may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Ingredient matches for Gammamix
Amoxicillin
Amoxicillin trihydrate (a derivative of Amoxicillin) is reported as an ingredient of Gammamix in the following countries:
- Italy
International Drug Name Search
RatioSoft
RatioSoft may be available in the countries listed below.
Ingredient matches for RatioSoft
Xylometazoline
Xylometazoline hydrochloride (a derivative of Xylometazoline) is reported as an ingredient of RatioSoft in the following countries:
- Austria
International Drug Name Search
Ceclor CD
In the US, Ceclor CD is a member of the drug class second generation cephalosporins and is used to treat Bladder Infection, Bronchitis, Kidney Infections, Otitis Media, Pneumonia, Sinusitis, Skin and Structure Infection, Skin Infection, Tonsillitis/Pharyngitis, Upper Respiratory Tract Infection and Urinary Tract Infection.
Ingredient matches for Ceclor CD
Cefaclor
Cefaclor monohydrate (a derivative of Cefaclor) is reported as an ingredient of Ceclor CD in the following countries:
- Bangladesh
International Drug Name Search
Troxeven
Troxeven may be available in the countries listed below.
Ingredient matches for Troxeven
Troxerutin
Troxerutin is reported as an ingredient of Troxeven in the following countries:
- Germany
International Drug Name Search
Friday, October 21, 2016
Glucagon Emergency
Ingredient matches for Glucagon Emergency
Glucagon
Glucagon is reported as an ingredient of Glucagon Emergency in the following countries:
- United States
International Drug Name Search
Ampicilina Drawer
Ampicilina Drawer may be available in the countries listed below.
Ingredient matches for Ampicilina Drawer
Ampicillin
Ampicillin sodium salt (a derivative of Ampicillin) is reported as an ingredient of Ampicilina Drawer in the following countries:
- Argentina
International Drug Name Search
Ambroxol Generis
Ambroxol Generis may be available in the countries listed below.
Ingredient matches for Ambroxol Generis
Ambroxol
Ambroxol hydrochloride (a derivative of Ambroxol) is reported as an ingredient of Ambroxol Generis in the following countries:
- Portugal
International Drug Name Search
Thursday, October 20, 2016
Ranitidine Duopharma
Ranitidine Duopharma may be available in the countries listed below.
Ingredient matches for Ranitidine Duopharma
Ranitidine
Ranitidine is reported as an ingredient of Ranitidine Duopharma in the following countries:
- Hong Kong
International Drug Name Search
Beatizem
Beatizem may be available in the countries listed below.
Ingredient matches for Beatizem
Diltiazem
Diltiazem hydrochloride (a derivative of Diltiazem) is reported as an ingredient of Beatizem in the following countries:
- Singapore
International Drug Name Search
Butamol
Butamol may be available in the countries listed below.
Ingredient matches for Butamol
Salbutamol
Salbutamol sulfate (a derivative of Salbutamol) is reported as an ingredient of Butamol in the following countries:
- Argentina
- Australia
International Drug Name Search
Rhinospray Eucaliptus
Rhinospray Eucaliptus may be available in the countries listed below.
Ingredient matches for Rhinospray Eucaliptus
Tramazoline
Tramazoline is reported as an ingredient of Rhinospray Eucaliptus in the following countries:
- Spain
International Drug Name Search
Wednesday, October 19, 2016
Caltate
Caltate may be available in the countries listed below.
Ingredient matches for Caltate
Calcium Lactate
Calcium Lactate is reported as an ingredient of Caltate in the following countries:
- Bangladesh
International Drug Name Search
Enalagamma HCT
Enalagamma HCT may be available in the countries listed below.
Ingredient matches for Enalagamma HCT
Enalapril
Enalapril maleate (a derivative of Enalapril) is reported as an ingredient of Enalagamma HCT in the following countries:
- Germany
Hydrochlorothiazide
Hydrochlorothiazide is reported as an ingredient of Enalagamma HCT in the following countries:
- Germany
International Drug Name Search
Captopril / Hydrochloorthiazide PCH
Captopril / Hydrochloorthiazide PCH may be available in the countries listed below.
Ingredient matches for Captopril / Hydrochloorthiazide PCH
Captopril
Captopril is reported as an ingredient of Captopril / Hydrochloorthiazide PCH in the following countries:
- Netherlands
Hydrochlorothiazide
Hydrochlorothiazide is reported as an ingredient of Captopril / Hydrochloorthiazide PCH in the following countries:
- Netherlands
International Drug Name Search
Préviscan
Préviscan may be available in the countries listed below.
Ingredient matches for Préviscan
Fluindione
Fluindione is reported as an ingredient of Préviscan in the following countries:
- France
- Luxembourg
International Drug Name Search
Apo-Nadol
Apo-Nadol may be available in the countries listed below.
Ingredient matches for Apo-Nadol
Nadolol
Nadolol is reported as an ingredient of Apo-Nadol in the following countries:
- Canada
International Drug Name Search
Anco
Anco may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Ingredient matches for Anco
Dimpylate
Dimpylate is reported as an ingredient of Anco in the following countries:
- Portugal
Ibuprofen
Ibuprofen is reported as an ingredient of Anco in the following countries:
- Germany
International Drug Name Search
Fluonid
In the US, Fluonid is a member of the drug class topical steroids and is used to treat Atopic Dermatitis, Dermatitis and Lichen Sclerosus.
Ingredient matches for Fluonid
Fluocinolone
Fluocinolone Acetonide is reported as an ingredient of Fluonid in the following countries:
- Hong Kong
International Drug Name Search
Tuesday, October 18, 2016
Clobegalen
Clobegalen may be available in the countries listed below.
Ingredient matches for Clobegalen
Clobetasol
Clobetasol 17α-propionate (a derivative of Clobetasol) is reported as an ingredient of Clobegalen in the following countries:
- Germany
International Drug Name Search
Fumarufen
Fumarufen may be available in the countries listed below.
Ingredient matches for Fumarufen
Ketotifen
Ketotifen fumarate (a derivative of Ketotifen) is reported as an ingredient of Fumarufen in the following countries:
- Japan
International Drug Name Search
Axo
Axo may be available in the countries listed below.
Ingredient matches for Axo
Atorvastatin
Atorvastatin calcium (a derivative of Atorvastatin) is reported as an ingredient of Axo in the following countries:
- Colombia
- Dominican Republic
- El Salvador
- Guatemala
- Honduras
- Nicaragua
- Panama
International Drug Name Search
Chlormézanone
Chlormézanone may be available in the countries listed below.
Ingredient matches for Chlormézanone
Chlormezanone
Chlormézanone (DCF) is known as Chlormezanone in the US.
International Drug Name Search
Glossary
| DCF | Dénomination Commune Française |
Click for further information on drug naming conventions and International Nonproprietary Names.
Micromycin
Micromycin may be available in the countries listed below.
Ingredient matches for Micromycin
Minocycline
Minocycline hydrochloride (a derivative of Minocycline) is reported as an ingredient of Micromycin in the following countries:
- Mexico
International Drug Name Search
Carbocisteina DOC
Carbocisteina DOC may be available in the countries listed below.
Ingredient matches for Carbocisteina DOC
Carbocisteine
Carbocisteine is reported as an ingredient of Carbocisteina DOC in the following countries:
- Italy
International Drug Name Search
Hikma Midazolam
Hikma Midazolam may be available in the countries listed below.
Ingredient matches for Hikma Midazolam
Midazolam
Midazolam is reported as an ingredient of Hikma Midazolam in the following countries:
- Bahrain
- Oman
- Tunisia
International Drug Name Search
Acidum Boricum
Acidum Boricum may be available in the countries listed below.
Ingredient matches for Acidum Boricum
Boric Acid
Boric Acid is reported as an ingredient of Acidum Boricum in the following countries:
- Georgia
International Drug Name Search
Monday, October 17, 2016
Biotrim Balsámico
Biotrim Balsámico may be available in the countries listed below.
Ingredient matches for Biotrim Balsámico
Guaifenesin
Guaifenesin is reported as an ingredient of Biotrim Balsámico in the following countries:
- Peru
Sulfamethoxazole
Sulfamethoxazole is reported as an ingredient of Biotrim Balsámico in the following countries:
- Peru
Trimethoprim
Trimethoprim is reported as an ingredient of Biotrim Balsámico in the following countries:
- Peru
International Drug Name Search
Mozasef
Mozasef may be available in the countries listed below.
Ingredient matches for Mozasef
Mosapride
Mosapride is reported as an ingredient of Mozasef in the following countries:
- India
International Drug Name Search
Risperidone Hexal
Risperidone Hexal may be available in the countries listed below.
Ingredient matches for Risperidone Hexal
Risperidone
Risperidone is reported as an ingredient of Risperidone Hexal in the following countries:
- Poland
- South Africa
International Drug Name Search
Losartan Hexal comp. 50mg / 12.2mg
Losartan Hexal comp. 50mg/12.2mg may be available in the countries listed below.
Ingredient matches for Losartan Hexal comp. 50mg/12.2mg
Hydrochlorothiazide
Hydrochlorothiazide is reported as an ingredient of Losartan Hexal comp. 50mg/12.2mg in the following countries:
- Germany
Losartan
Losartan potassium salt (a derivative of Losartan) is reported as an ingredient of Losartan Hexal comp. 50mg/12.2mg in the following countries:
- Germany
International Drug Name Search
Mecadox Plus
Mecadox Plus may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Ingredient matches for Mecadox Plus
Carbadox
Carbadox is reported as an ingredient of Mecadox Plus in the following countries:
- New Zealand
Morantel
Morantel citrate (a derivative of Morantel) is reported as an ingredient of Mecadox Plus in the following countries:
- New Zealand
International Drug Name Search
Sunday, October 16, 2016
Paridon
Paridon may be available in the countries listed below.
Ingredient matches for Paridon
Domperidone
Domperidone is reported as an ingredient of Paridon in the following countries:
- Bangladesh
International Drug Name Search
Jutadol
Jutadol may be available in the countries listed below.
Ingredient matches for Jutadol
Tramadol
Tramadol hydrochloride (a derivative of Tramadol) is reported as an ingredient of Jutadol in the following countries:
- Germany
International Drug Name Search
Carboplatin Bendalis
Carboplatin Bendalis may be available in the countries listed below.
Ingredient matches for Carboplatin Bendalis
Carboplatin
Carboplatin is reported as an ingredient of Carboplatin Bendalis in the following countries:
- Germany
International Drug Name Search
Isoptino
Isoptino may be available in the countries listed below.
Ingredient matches for Isoptino
Verapamil
Verapamil hydrochloride (a derivative of Verapamil) is reported as an ingredient of Isoptino in the following countries:
- Argentina
International Drug Name Search
Saturday, October 15, 2016
Prones
Prones may be available in the countries listed below.
Ingredient matches for Prones
Benzocaine
Benzocaine is reported as an ingredient of Prones in the following countries:
- Japan
Cinchocaine
Cinchocaine hydrochloride (a derivative of Cinchocaine) is reported as an ingredient of Prones in the following countries:
- Japan
International Drug Name Search
Primace
Primace may be available in the countries listed below.
Ingredient matches for Primace
Ramipril
Ramipril is reported as an ingredient of Primace in the following countries:
- Bangladesh
International Drug Name Search
Lenamet Otc
Lenamet Otc may be available in the countries listed below.
Ingredient matches for Lenamet Otc
Cimetidine
Cimetidine is reported as an ingredient of Lenamet Otc in the following countries:
- South Africa
International Drug Name Search
Tadalafil
In the US, Tadalafil (tadalafil systemic) is a member of the drug class impotence agents and is used to treat Erectile Dysfunction and Pulmonary Arterial Hypertension.
US matches:
- Tadalafil
Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
G04BE08
CAS registry number (Chemical Abstracts Service)
0171596-29-5
Chemical Formula
C22-H19-N3-O4
Molecular Weight
389
Therapeutic Categories
Vasodilator
Treatment of erectile dysfunction
Chemical Names
(6R,12aR)-6-(1,3-Benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione (WHO)
Pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione, 6-(1,3-benzo-dioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R-12aR)- (USAN)
Foreign Names
- Tadalafilum (Latin)
- Tadalafil (German)
- Tadalafil (French)
- Tadalafilo (Spanish)
Generic Names
- Tadalafil (OS: USAN, BAN)
- EP 740668 B 1998 (IS)
- GF 196960 (IS)
- GG 960 (IS)
- IC 351 (IS: LillyICOS)
- ICOS 351 (IS)
Brand Names
- Adcirca
Eli Lilly, United States; Lilly, Germany - Apcalis
Ajanta, Georgia - Cialis
Eli Lilly, Canada; Eli Lilly, United Kingdom; Eli Lilly, Indonesia; Eli Lilly, Netherlands; Eli Lilly, Oman; Eli Lilly, Vietnam; Eli Lilly, South Africa; Lilly, Argentina; Lilly, Austria; Lilly, Australia; Lilly, Bosnia & Herzegowina; Lilly, Belgium; Lilly, Bahrain; Lilly, Brazil; Lilly, Switzerland; Lilly, Chile; Lilly, Colombia; Lilly, Costa Rica; Lilly, Czech Republic; Lilly, Germany; Lilly, Denmark; Lilly, Dominican Republic; Lilly, Spain; Lilly, Finland; Lilly, France; Lilly, Georgia; Lilly, Greece; Lilly, Guatemala; Lilly, Hong Kong; Lilly, Honduras; Lilly, Croatia (Hrvatska); Lilly, Hungary; Lilly, Ireland; Lilly, Israel; Lilly, Iceland; Lilly, Italy; Lilly, Sri Lanka; Lilly, Luxembourg; Lilly, Mexico; Lilly, Malaysia; Lilly, Nicaragua; Lilly, Norway; Lilly, New Zealand; Lilly, Panama; Lilly, Peru; Lilly, Philippines; Lilly, Portugal; Lilly, Romania; Lilly, Serbia; Lilly, Russian Federation; Lilly, Sweden; Lilly, Singapore; Lilly, Slovenia; Lilly, Slovakia; Lilly, El Salvador; Lilly, Thailand; Lilly, Turkey; Lilly, Taiwan; Lilly, United States; Lilly, Venezuela; Whitehall, Luxembourg - Forzest
Ranbaxy, India - Snafi
Spimaco, Oman - Zydalis
Zydus Cadila, India
International Drug Name Search
Glossary
| BAN | British Approved Name |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
| WHO | World Health Organization |
Click for further information on drug naming conventions and International Nonproprietary Names.
Mebron
Mebron may be available in the countries listed below.
Ingredient matches for Mebron
Epirizole
Epirizole is reported as an ingredient of Mebron in the following countries:
- Japan
- Taiwan
International Drug Name Search
Ceprametacin
Ceprametacin may be available in the countries listed below.
Ingredient matches for Ceprametacin
Cefmetazole
Cefmetazole sodium salt (a derivative of Cefmetazole) is reported as an ingredient of Ceprametacin in the following countries:
- Japan
International Drug Name Search
Myolastan
Myolastan may be available in the countries listed below.
Ingredient matches for Myolastan
Tetrazepam
Tetrazepam is reported as an ingredient of Myolastan in the following countries:
- Austria
- Belgium
- Chile
- Costa Rica
- Czech Republic
- Dominican Republic
- Ecuador
- El Salvador
- France
- Guatemala
- Honduras
- Latvia
- Lithuania
- Luxembourg
- Nicaragua
- Panama
- Peru
- Poland
- Romania
- Serbia
- Slovakia
- Spain
- Tunisia
International Drug Name Search
Friday, October 14, 2016
Paxirasol
Paxirasol may be available in the countries listed below.
Ingredient matches for Paxirasol
Bromhexine
Bromhexine is reported as an ingredient of Paxirasol in the following countries:
- Vietnam
Bromhexine hydrochloride (a derivative of Bromhexine) is reported as an ingredient of Paxirasol in the following countries:
- Czech Republic
- Hungary
International Drug Name Search
Cefade
Cefade may be available in the countries listed below.
Ingredient matches for Cefade
Cefalotin
Cefalotin is reported as an ingredient of Cefade in the following countries:
- Argentina
International Drug Name Search
Asentra
Asentra may be available in the countries listed below.
Ingredient matches for Asentra
Sertraline
Sertraline is reported as an ingredient of Asentra in the following countries:
- Slovenia
Sertraline hydrochloride (a derivative of Sertraline) is reported as an ingredient of Asentra in the following countries:
- Bosnia & Herzegowina
- Bulgaria
- Croatia (Hrvatska)
- Czech Republic
- Estonia
- Hungary
- Latvia
- Lithuania
- Poland
- Romania
- Russian Federation
- Serbia
- Slovakia
International Drug Name Search
Roglit
Roglit may be available in the countries listed below.
Ingredient matches for Roglit
Rosiglitazone
Rosiglitazone is reported as an ingredient of Roglit in the following countries:
- Georgia
- Russian Federation
International Drug Name Search
Thursday, October 13, 2016
Tocainide Hydrochloride
Tocainide Hydrochloride may be available in the countries listed below.
Ingredient matches for Tocainide Hydrochloride
Tocainide
Tocainide Hydrochloride (BANM) is known as Tocainide in the US.
International Drug Name Search
Glossary
| BANM | British Approved Name (Modified) |
Click for further information on drug naming conventions and International Nonproprietary Names.
Tamoxifen PCH
Tamoxifen PCH may be available in the countries listed below.
Ingredient matches for Tamoxifen PCH
Tamoxifen
Tamoxifen citrate (a derivative of Tamoxifen) is reported as an ingredient of Tamoxifen PCH in the following countries:
- Netherlands
International Drug Name Search
Wednesday, October 12, 2016
Isosorbide dinitraat Fagron
Isosorbide dinitraat Fagron may be available in the countries listed below.
Ingredient matches for Isosorbide dinitraat Fagron
Isosorbide Dinitrate
Isosorbide Dinitrate is reported as an ingredient of Isosorbide dinitraat Fagron in the following countries:
- Netherlands
International Drug Name Search
Genagra
Genagra may be available in the countries listed below.
Ingredient matches for Genagra
Sildenafil
Sildenafil citrate (a derivative of Sildenafil) is reported as an ingredient of Genagra in the following countries:
- Georgia
International Drug Name Search
Paraplatin
In some countries, this medicine may only be approved for veterinary use.
In the US, Paraplatin (carboplatin systemic) is a member of the drug class alkylating agents and is used to treat Cancer, Cervical Cancer and Ovarian Cancer.
US matches:
- Paraplatin
- Paraplatin NovaPlus
Ingredient matches for Paraplatin
Carboplatin
Carboplatin is reported as an ingredient of Paraplatin in the following countries:
- Bahrain
- Belgium
- Bosnia & Herzegowina
- Brazil
- China
- Colombia
- Croatia (Hrvatska)
- Egypt
- Estonia
- Finland
- Greece
- Hong Kong
- Hungary
- Iceland
- Iran
- Iraq
- Ireland
- Italy
- Japan
- Jordan
- Kuwait
- Lebanon
- Lithuania
- Luxembourg
- Mexico
- Oman
- Philippines
- Poland
- Portugal
- Qatar
- Saudi Arabia
- Serbia
- Singapore
- Slovenia
- South Africa
- Switzerland
- Syria
- Taiwan
- Thailand
- United Arab Emirates
- United Kingdom
- United States
- Yemen
International Drug Name Search
Azitromicina Bluepharma
Azitromicina Bluepharma may be available in the countries listed below.
Ingredient matches for Azitromicina Bluepharma
Azithromycin
Azithromycin is reported as an ingredient of Azitromicina Bluepharma in the following countries:
- Portugal
International Drug Name Search
Wilate®
1. Name Of The Medicinal Product
Wilate
Wilate
2. Qualitative And Quantitative Composition
Wilate is presented as a powder and solvent for solution for injection containing nominally 450 IU/900 IU human coagulation factor VIII and 400 IU/800 IU human von Willebrand factor (VWF) per vial.
The product contains approximately 80 IU/ml human von Willebrand factor when reconstituted with 5 ml/10 ml Water for Injections with 0.1 % Polysorbat 80.
The specific activity of Wilate is approximately
The VWF potency (IU) is measured according to ristocetin cofactor activity (VWF:RCo) compared to the International Standard for von Willebrand Factor Concentrate (WHO).
The product contains approximately 90 IU/ml human coagulation factor VIII when reconstituted with 5 ml/10 ml Water for Injections with 0.1% Polysorbate 80.
The FVIII potency (IU) is determined using the European Pharmacopoeia chromogenic assay. The specific activity of Wilate is approximately
For a full list of excipients, see 6.1.
3. Pharmaceutical Form
Powder and solvent for solution for injection.
4. Clinical Particulars
4.1 Therapeutic Indications
Von Willebrand disease (VWD)
Prevention and treatment of haemorrhage or surgical bleeding in von Willebrand disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or contra-indicated.
Haemophilia A
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital FVIII deficiency) .
4.2 Posology And Method Of Administration
Treatment should be initiated under the supervision of a physician experienced in the treatment of coagulation disorders. The product is of single use and the full content of the vial should be administered. In case any content remains, it should be disposed of in accordance with local requirements.
Von Willebrand disease (VWD)
The ratio between FVIII:C and VWF:RCo is roughly 1:1. Generally, 1 IU/kg BW FVIII:C and VWF:RCo raises the plasma level by 1.5-2% of normal activity for the respective protein. Usually, about 20 to 50 IU Wilate/kg BW are necessary to achieve adequate haemostasis. This will raise the FVIII:C and VWF:RCo in the patients by approx. 30 to 100%.
An initial dose of 50 to 80 IU Wilate/kg BW may be required, especially in patients with VWD type 3, where the maintenance of adequate plasma levels may require higher doses than in other types of VWD.
Prevention of haemorrhage in case of surgery or severe trauma:
For prevention of bleeding in case of surgery, Wilate should be given 1-2 hours before start of the surgical procedure. Levels of VWF:RCo of
An appropriate dose should be re-administered every 12-24 hours of treatment. The dose and duration of the treatment depend on the clinical status of the patient, the type and severity of bleeding, and both FVIII:C and VWF:RCo levels.
In patients receiving FVIII-containing VWF products, plasma levels of FVIII:C should be monitored to reveal sustained excessive FVIII:C plasma levels, which may increase the risk of thrombotic events, particularly in patients with known clinical or laboratory risk factors. In case excessive FVIII:C plasma levels are observed, reduced doses and/or prolongation of the dose interval or the use of VWF product containing a low level of FVIII should be considered.
Prophylaxis:
For long term prophylaxis against bleeds in VWD patients, doses of 20-40 IU/kg bodyweight should be administered 2 or 3 times per week. In some cases, such as in patients with gastrointestinal bleeds, higher doses may be necessary.
Haemophilia A
The dosage and duration of the substitution therapy depend on the severity of the FVIII deficiency, on the location and extent of the bleeding and on the patient's clinical condition.
The number of units of FVIII administered is expressed in International Units (IU), which are related to the current WHO standard for FVIII products. FVIII activity in plasma is expressed either as a percentage (relative to normal human plasma) or in IU (relative to an International Standard for FVIII in plasma).
One IU of FVIII activity is equivalent to that quantity of FVIII in one ml of normal human plasma.
The calculation of the required dosage of FVIII is based on the empirical finding that 1 IU FVIII:C/kg BW raises the plasma level by 1.5-2% of normal activity. The required dosage is determined using the following formula:
Required IU = BW (kg) x desired FVIII rise (%) (IU/dl) x 0.5 IU/kg
The amount to be administered and the frequency of administration should always be oriented to the clinical effectiveness in the individual case. In the case of the following haemorrhagic events, the factor VIII activity should not fall below the given plasma activity level (in % of normal or IU/dl) in the corresponding period. The following table can be used to guide dosing in bleeding episodes and surgery.
Treatment scheme for Haemorrhages and Surgery
|
|
|
| ||
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
Prophylaxis:
For long-term prophylaxis against bleedings in patients with severe haemophilia A, doses of 20 to 40 IU Wilate/kg BW should be given at intervals of 2 to 3 days. In some cases, especially in younger patients, shorter dosage intervals or higher doses may be necessary.
Continuous infusion:
Prior to surgery, a pharmacokinetic analysis should be performed to obtain an estimate of clearance. The initial infusion rate can be calculated as follows:
Infusion rate (IU/kg/h) = clearance (mL/kg/h) x desired steady state level (IU/mL)
After the initial 24 hours of continuous infusion, the clearance should be calculated again every day using the steady state equation with the measured level and the known rate of infusion.
During the course of treatment, appropriate determination of FVIII:C levels is advised to guide the dose to be administered and the frequency of repeated infu-sions. In the case of major surgical interventions in particular, precise monitoring of the substitution therapy by means of coagulation analysis (FVIII:C) is indispensable. Individual patients may vary in their response to FVIII treatment, achieving different levels of in vivo recovery and demonstrating different half-lives.
Patients should be monitored for the development of FVIII neutralising antibodies (inhibitors). If the expected FVIII activity plasma levels are not attained, or if bleeding is not controlled with an appropriate dose, an assay should be performed to determine if a FVIII inhibitor is present. In patients with high levels of inhibitor, FVIII therapy may not be effective and other therapeutic options should be considered. Management of such patients should be directed by physicians with experience in the care of patients with haemostatic disorders. See also 4.4.
There are insufficient data to recommend the use of Wilate in children less than 6 years old.
Method of administration
For intravenous injection after reconstitution with the enclosed solvent. See 6.6.
The injection or infusion rate should not exceed 2-3 ml per minute.
4.3 Contraindications
Hypersensitivity to the active substances or to any of the excipients.
4.4 Special Warnings And Precautions For Use
As with any intravenous infusion of a plasma-derived protein product, allergic type hypersensitivity reactions are possible. Patients must be closely monitored and carefully observed for any symptoms throughout the infusion period.
Patients should be informed of the early signs of hypersensitivity reactions in-cluding hives, generalised urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis. If allergic symptoms occur, patients should discontinue the administration immediately and contact their physician.
In case of shock, the current medical standards for treatment of shock are to be observed.
Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens.
The measures taken are considered effective for enveloped viruses such as HIV, HBV and HCV, and for the non-enveloped virus HAV. The measures taken may be of limited value against non-enveloped viruses such as parvovirus B19.
Parvovirus B19 infection may be serious for pregnant women (fetal infection) and for individuals with immunodeficiency or increased erythropoiesis (e.g. haemolytic anaemia).
It is strongly recommended that every time that Wilate is administered to a patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the product.
Appropriate vaccination (hepatitis A and B) should be considered for patients in regular/repeated receipt of human plasma-derived FVIII/VWF concentrates.
Von Willebrand disease (VWD)
When using a FVIII-containing VWF product, the treating physician should be aware that continued treatment may cause an excessive rise in FVIII:C. In patients receiving FVIII-containing VWF products, plasma levels of FVIII:C should be monitored to avoid sustained excessive FVIII:C plasma levels, which may increase the risk of thrombotic events.
There is a risk of occurence of thrombotic events when using FVIII-containing VWF products, particularly in patients with known clinical or laboratory risk factors. Therefore, patients at risk must be monitored for early signs of thrombosis. Prophylaxis against venous thromboembolism should be instituted, according to the current recommendations.
Patients with VWD, especially type 3 patients, may develop neutralising antibodies (inhibitors) to VWF. If the expected VWF:RCo activity plasma levels are not attained, or if bleeding is not controlled with an appropriate dose, an appropriate assay should be performed to determine if a VWF inhibitor is present. In patients with high levels of inhibitor, VWF therapy may not be effective and other therapeutic options should be considered. Management of such patients should be directed by physicians with experience in the care of patients with haemostatic disorders.
Haemophilia A
The formation of neutralising antibodies (inhibitors) to FVIII is a known complication in the management of individuals with haemophilia A. These inhibitors are usually IgG immunoglobulins directed against the FVIII procoagulant activity, which are quantified in Modified Bethesda Units (BU) per mL of plasma using the modified assay. The risk of developing inhibitors is correlated to the exposure to anti-haemophilic FVIII, this risk being highest within the first 20 exposure days. Rarely, inhibitors may develop after the first 100 exposure days. Patients treated with FVIII should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory test. (see also 4.8)..
Cases of recurrent inhibitor (low titre) have been observed after switching from one FVIII product to another in previously treated patients with more than 100 exposure days who have a previous history of inhibitor development. Therefore, it is recommended to monitor patients carefully for inhibitor occurrence following any product switch.
This medicinal product contains up to 2.55 mmol sodium (58.7 mg) per dose for 450 IU FVIII and 400 IU VWF/vial and up to 5.1 mmol sodium (117.3 mg) per dose for 900 IU FVIII and 800 IU VWF/vial. To be taken into consideration by patients on a controlled sodium diet.
4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction
No interactions with other medicinal products are known.
4.6 Pregnancy And Lactation
Animal reproduction studies have not been conducted with FVIII/VWF.
Von Willebrand disease (VWD)
Experience in the treatment of pregnant or lactating women is not available.
Wilate should be administered to pregnant or lactating VWF deficient women only if clearly indicated, taking into consideration that delivery confers an increased risk of haemorrhagic events in these patients.
Haemophilia A
Based on the rare occurrence of haemophilia A in women, experience regarding the treatment during pregnancy and breastfeeding is not available. Therefore, Wilate should be used during pregnancy and lactation only if clearly indicated.
4.7 Effects On Ability To Drive And Use Machines
No effects on ability to drive and use machines have been observed.
4.8 Undesirable Effects
Hypersensitivity or allergic reactions (which may include angiooedema, burning and stinging at the infusion site, chills, flushing, generalised urticaria, headache, hives, hypotension, lethargy, nausea, restlessness, tachycardia, tightness of the chest, tingling, vomiting, wheezing) have been observed infrequently, and may in some cases progress to severe anaphylaxis (including shock). In rare occasions, fever has been observed.
|
|
|
|
|
|
| |
|
| ||
|
|
|
uncommon (> 1/1,000, < 1/100)
rare (>1/10,000, <1/1,000)
very rare (<1/10,000), including isolated reports
Von Willebrand disease (VWD)
Patients with VWD, especially type 3 patients, may very rarely develop neutralising antibodies to VWF. If such inhibitors occur, the condition will manifest itself as an inadequate clinical response. Such antibodies may precipitate and may occur concomitantly to anaphylactic reactions. Therefore, patients experiencing anaphylactic reaction should be evaluated for the presence of an inhibitor.
In all such cases, it is recommended that a specialised haemophilia centre be contacted.
No cases of inhibitors for von Willebrand factor have been reported from clinical studies or from post marketing experience for Wilate so far.
There is a risk of occurrence of thrombotic events, particularly in patients with known clinical or laboratory risk factors. Therefore, patients at risk must be monitored for early signs of thrombosis. Prophylaxis against venous thromboembolism should be instituted, according to the current recommendations.
In patients receiving FVIII-containing VWF products sustained excessive FVIII:C plasma levels may increase the risk of thrombotic events.
Haemophilia A
Patients with haemophilia A may develop neutralising antibodies (inhibitors) to FVIII. If such inhibitors occur, the condition will manifest as an insufficient clinical response. In such cases, it is recommended that a specialised haemophilia centre be contacted.
The experience with Wilate in previously untreated patients (PUPs) is limited. In a clinical trial involving 24 PUPs with a minimum of 50 exposure days treated with Wilate, only three patients with a persistent and clinically manifest inhibitor above 5 BU/ml could be detected. Three patients developed low titre, transient inhibitors without any clinical manifestations, and two patients had a low titre inhibitor on a single occasion with no follow-up result.
See also section 4.2. There were no inhibitor developments observed in previously treated patients.
For safety with respect to transmissible agents, see 4.4
4.9 Overdose
No symptoms of overdose with human FVIII or VWF have been reported. Thromboembolic events may occur in case of major overdose.
5. Pharmacological Properties
5.1 Pharmacodynamic Properties
Pharmacotherapeutic group: Antihaemorrhagics: blood coagulation factors Von Willebrand factor and coagulation factor VIII in combination
ATC Code: B02BD06
Von Willebrand disease (VWD)
The VWF (from the concentrate) is a normal constituent of the human plasma and behaves in the same way as endogenous VWF.
Administration of VWF allows correction of the haemostatic abnormalities exhibited in patients who suffer from VWF deficiency (VWD) at two levels:
− VWF re-establishes platelet adhesion to the vascular sub-endothelium at the site of vascular damage (as it binds both to the vascular sub-endothelium and to the platelet membrane), providing primary haemostasis as shown by the shortening of the bleeding time. This effect occurs immediately and is known to depend to a large extent to the level of polymerisation of the protein;
− VWF produces delayed correction of the associated FVIII deficiency. Administered intravenously, VWF binds endogenous FVIII (which is produced normally by the patient), and by stabilising this factor, avoids its rapid degradation.
Because of this, administration of pure VWF (VWF product with a low FVIII level) restores the FVIII:C level to normal as a secondary effect after first infusion.
Administration of a FVIII-containing VWF preparation restores the FVIII:C level to normal immediately after first infusion.
In addition to its role as a FVIII-protecting protein, VWF mediates platelet adhesion to sites of vascular injury and plays a role in platelet aggregation.
Haemophilia A
The FVIII/VWF complex consists of two molecules (FVIII and VWF) with different physiological functions. When infused into a haemophilia patient, FVIII binds to VWF in the patient´s circulation. Activated FVIII (FVIIIa) acts as a cofactor for activated factor IX (FIXa), accelerating the conversion of factor X to activated factor X (FXa). FXa converts prothrombin into thrombin. Thrombin then converts fibrinogen into fibrin and a clot can be formed.
Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of FVIII: C and results in profuse bleeding into joints, muscles or internal organs, either spontaneously or as a result of accidental or surgical trauma. By replacement therapy the plasma levels of FVIII are increased, thereby enabling a temporary correction of the factor deficiency and correction of the bleeding tendencies.
5.2 Pharmacokinetic Properties
Von Willebrand disease (VWD)
VWF (from the concentrate) is a normal constituent of the human plasma and acts like the endogenous VWF.
Based on meta-analysis of three pharmacokinetic studies involving 24 evaluable patients with all VWD types, the following results were observed.
|
|
|
| |||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Key: AUC = area under the curve; MRT = mean residence time
Haemophilia A
FVIII (from the concentrate) is a normal constituent of the human plasma and acts like the endogenous FVIII. After injection of the product, approximately two thirds to three quarters of the FVIII remain in the circulation. The level of FVIII:C reached in the plasma should be between 80-120% of the predicted FVIII:C.
FVIII:C decreases by a two-phase exponential decay. In the initial phase, distribution between the intravascular and other compartments (body fluids) occurs with a half-life of elimination from the plasma of 3 to 6 hours. In the subsequent slower phase, the half-life varies between 8 to 18 hours, with an average of 15 hours. This corresponds to the true biological half-life.
The following results were observed in one clinical study in 12 patients (chromogenic assay, double measurements):
|
|
| ||
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Key: AUC = area under the curve; MRT = mean residence time; SD = standard deviation
5.3 Preclinical Safety Data
FVIII and VWF in Wilate are normal constituents of the human plasma and act like the endogenous FVIII/VWF.
Conventional safety testing of these compounds in laboratory animals would not add useful information to the existing clinical experience and therefore is not required.
6. Pharmaceutical Particulars
6.1 List Of Excipients
Powder: Sodium chloride, Glycine, Sucrose, Sodium citrate and Calcium chloride
Solvent: Water for injections with 0.1 % Polysorbate 80
6.2 Incompatibilities
Wilate must not be mixed with other medicinal products or administered simultaneously with other intravenous preparation in the same infusion set.
Only the provided injection/infusion sets can be used because treatment failure can occur as a consequence of FVIII/VWF adsorption to the internal surfaces of some infusion equipment.
6.3 Shelf Life
3 years.
The stability of the reconstituted solution has been demonstrated for 12 hours at room temperature (max. +25°C). Nevertheless, to avoid microbial contamination, the reconstituted solution should be used immediately.
6.4 Special Precautions For Storage
Store powder and solvent vial in a refrigerator (+2-8°C). Keep the vials in the outer carton to protect from light. Do not freeze.
The product can be stored at room temperature (max. +25°C) for 2 months. In this case the shelf-life expires 2 months after the product has been taken out of the refrigerator for the first time. The new shelf-life has to be noted on the outer carton by the patient. The reconstituted solution should be used on one occasion only. Any solution remaining should be discarded.
6.5 Nature And Contents Of Container
Package sizes:
Wilate 450, 450 IU FVIII and 400 IU VWF
1 package contains:
1 vial with Powder, type I glass, closed with a stopper (bromobutyl rubber) and sealed with a flip off cap1 vial with Solvent (5 ml Water for Injections with 0.1% Polysorbate 80), type I glass, closed with a stopper (chlorobutyl rubber) and sealed with a flip off cap
1 equipment pack with the medical devices (1 disposable syringe, 1 transfer set [1 double-ended needle and 1 filter needle], 1 infusion set)
2 alcohol swabs
Wilate 900, 900 IU FVIII and 800 IU VWF
1 package contains:
1 vial with Powder, type I glass, closed with a stopper (bromobutyl rubber) and sealed with a flip off cap
1 vial with Solvent (10 ml Water for Injections with 0.1% Polysorbate 80), type I glass, closed with a stopper (chlorobutyl rubber) and sealed with a flip off cap
1 equipment pack with the medical devices (1 disposable syringe, 1 transfer set [1 double-ended needle and 1 filter needle], 1 infusion set)
2 alcohol swabs
6.6 Special Precautions For Disposal And Other Handling
1. Warm the solvent and the powder in the closed vials up to room temperature. If a water bath is used for warming, care must be taken to avoid water coming into contact with the rubber stoppers (latex-free) or the caps of the vials. The temperature of the water bath should not exceed +37°C.
2. Remove the caps from the powder vial and the solvent vial (Fig. A) and disinfect the rubber stoppers with an alcohol swab.
3. Place the solvent vial on a flat surface. Attach the double-ended needle with the wavy edging on the solvent vial (“Wave to Water”) and push down as far as will go (Fig. B).
4. Place the concentrate vial on a flat surface. Remove the protective cover from the double-ended needle, making sure not to touch the exposed tip of the needle. Hold the solvent vial with the double-ended needle upside-down and quickly perforate the centre of the concentrate vial rubber stopper with the needle and push down as far as will go (Fig. C). The vacuum inside the concentrate vial draws in the solvent.
5. Remove the solvent vial and the double-ended needle from the powder vial (Fig. D). Wilate dissolves quickly therefore only slowly rotate the vial.
The solution is clear to slightly opalescent. Cloudy solutions or solutions with aggregates must not be used.
Injection:
1. Remove the protective cover from the filter and perforate the rubber stopper of the concentrate vial (Fig. E).
2. Retract the piston of the syringe to draw in air.
3. Remove the closure from the filter and attach the syringe to the filter (Fig. Fa).
4. Inject the air into the vial (Fig. Fb).
5. Turn the vial with the attached syringe upside-down and draw the solution up into the syringe (Fig. G).
6. Remove the syringe from the filter.
7. Clean the intended injection site with an alcohol swab.
8. Attach the Butterfly to the syringe (Fig. H) and immediately inject the preparation intravenously. Injection speed: 2-3 ml per minute.
9. If the patient receives more than one vial of the concentrate, the same butterfly can be used. The syringe can also be used for several concentrate vials. Always use a new filter when drawing up the solution.
Any unused product or waste material should be disposed of in accordance with local requirements.
7. Marketing Authorisation Holder
Octapharma Limited
The Zenith Building
26 Spring Gardens
Manchester M2 1AB
United Kingdom
8. Marketing Authorisation Number(S)
PL 10673/0032
9. Date Of First Authorisation/Renewal Of The Authorisation
23/09/2009
10. Date Of Revision Of The Text
08/06/2010
11 DOSIMETRY
IF APPLICABLE
12 INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS
IF APPLICABLE
Subscribe to:
Comments (Atom)